Clinical Trial Update: Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for CAN1012, a selective TLR7 agonist, in subjects with solid tumors, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• CAN1012

Snippet

Sponsor: Canwell Biotech Limited | Conditions: Solid Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING